TSTickerStar
Company alerts/TVRD
TVRD company alerts

TVRD updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for TVRD. Subscribe to TVRD alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent TVRD alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Company updateOfficial company source

Tvardi receives FDA pre-IND feedback for TTI-109 in inflammatory bowel disease

Tvardi Therapeutics announced receipt of FDA written responses to its pre-IND meeting request for TTI-109, the company's next-generation oral STAT3 inhibitor for inflammatory bowel disease. The FDA agreed that the proposed nonclinical studies are appropriate to support a Phase 2 trial and provided guidance on dosing, study design, and patient selection. The company plans to submit an IND in 2027, with Phase 2 initiation subject to FDA clearance and additional funding availability. New analysis of Phase 1 exposur...

Read source-backed brief
EarningsOfficial company source

Tvardi Therapeutics Reports Q3 2026 Results; Net Loss Widens to $6.1M on Higher R&D Spend

Tvardi Therapeutics reported a Q3 2026 net loss of $6.1 million compared to a net loss of $5.5 million in Q3 2025, as R&D expenses increased to $4.5 million from $3.6 million driven by higher clinical costs for TTI-101. Basic and diluted net loss per share improved to $(0.48) from $(0.59) year-over-year. The company ended Q3 2026 with $22.3 million in cash and cash equivalents, down from $30.8 million at year-end 2025, and expects this to fund operations into Q3 2027.

Read source-backed brief
SEC filingSEC filing

TVRD 10-Q filed 2026-11-13 | Key takeaways

TVRD filed its 10-Q; the most relevant disclosure change is expanded At-the-market equity offerings: During Q3 2026, the company sold 3,110,769 shares of common stock for $11.0 million under the Original Sales Agreement Prospectus and 853,843 shares for $2.3 million under the New Sales Agreement Prospectus Supplement, with total commissions and offering expen. Customer concentration: Vendor A represented 44% of operating_expenses; Vendor A represented 66% of accounts_payable.

Read source-backed brief